Docetaxel vs non‐docetaxel‐containing regimens
Overall survival ‐ Additive comparisons · people with advanced gastric cancer
Docetaxel probably leads to lower overall survival ‐ Additive comparisons compared with non‐docetaxel‐containing regimens (moderate certainty).
1 finding from 1 review
- HR 0.8 [0.71, 0.91]4 studies · 1466 participantsModerate